全文获取类型
| 收费全文 | 37858篇 |
| 免费 | 2589篇 |
| 国内免费 | 80篇 |
专业分类
| 耳鼻咽喉 | 271篇 |
| 儿科学 | 1060篇 |
| 妇产科学 | 1106篇 |
| 基础医学 | 5286篇 |
| 口腔科学 | 542篇 |
| 临床医学 | 5191篇 |
| 内科学 | 7157篇 |
| 皮肤病学 | 481篇 |
| 神经病学 | 3775篇 |
| 特种医学 | 925篇 |
| 外国民族医学 | 4篇 |
| 外科学 | 4245篇 |
| 综合类 | 426篇 |
| 一般理论 | 36篇 |
| 预防医学 | 4486篇 |
| 眼科学 | 582篇 |
| 药学 | 2219篇 |
| 中国医学 | 31篇 |
| 肿瘤学 | 2704篇 |
出版年
| 2023年 | 184篇 |
| 2022年 | 243篇 |
| 2021年 | 607篇 |
| 2020年 | 400篇 |
| 2019年 | 650篇 |
| 2018年 | 796篇 |
| 2017年 | 578篇 |
| 2016年 | 627篇 |
| 2015年 | 788篇 |
| 2014年 | 1090篇 |
| 2013年 | 1605篇 |
| 2012年 | 2338篇 |
| 2011年 | 2490篇 |
| 2010年 | 1307篇 |
| 2009年 | 1259篇 |
| 2008年 | 2219篇 |
| 2007年 | 2348篇 |
| 2006年 | 2257篇 |
| 2005年 | 2170篇 |
| 2004年 | 2172篇 |
| 2003年 | 2026篇 |
| 2002年 | 1993篇 |
| 2001年 | 767篇 |
| 2000年 | 739篇 |
| 1999年 | 632篇 |
| 1998年 | 426篇 |
| 1997年 | 375篇 |
| 1996年 | 300篇 |
| 1995年 | 296篇 |
| 1994年 | 285篇 |
| 1993年 | 226篇 |
| 1992年 | 471篇 |
| 1991年 | 420篇 |
| 1990年 | 415篇 |
| 1989年 | 382篇 |
| 1988年 | 388篇 |
| 1987年 | 364篇 |
| 1986年 | 354篇 |
| 1985年 | 342篇 |
| 1984年 | 266篇 |
| 1983年 | 219篇 |
| 1982年 | 165篇 |
| 1981年 | 159篇 |
| 1979年 | 182篇 |
| 1978年 | 177篇 |
| 1977年 | 151篇 |
| 1975年 | 162篇 |
| 1974年 | 190篇 |
| 1972年 | 143篇 |
| 1971年 | 140篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
Jennifer Weiss Ashley Glode Wells A. Messersmith 《Expert review of anticancer therapy》2019,19(8):673-679
Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-related death. Unlike hormone receptor-positive or HER2-positive breast cancers, there are limited targeted therapies available to treat TNBC and cytotoxic chemotherapy remains the mainstay of treatment. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate targeting Trop-2 expressing cells and selectively delivering SN-38, an active metabolite of irinotecan.
Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.
Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. 相似文献
2.
3.
4.
5.
6.
Digestive Diseases and Sciences - 相似文献
7.
Margaret H. Lauerman Karen Irizarry Clint Sliker Brandon R. Bruns Ronald Tesoriero Thomas M. Scalea Deborah M. Stein 《Injury》2019,50(1):131-136
Background
Current blunt cerebrovascular injury (BCVI) grading grossly differentiates injury characteristics such as luminal stenosis (LS) and aneurysmal disease. The effect of increasing degree of LS beyond the current BCVI grading scale on stroke formation is unknown.Study Design
BCVI over a 3-year period were retrospectively reviewed. To investigate influence of LS beyond the BCVI grading scale within aneurysmal and non-aneurysmal BCVI, grade 2 BCVI were subdivided into BCVI with ≥ 25% and ≤ 50% LS and BCVI with > 50% and ≤ 99% LS. Grade 3 BCVI were subdivided into BCVI with pseudoaneurysm (PSA) without LS and BCVI with PSA and LS. We hypothesized increased LS beyond the current BCVI grade distinctions would be associated with higher rates of stroke formation.Results
312 BCVI were included, of which 140 were carotid BCVI and 172 vertebral BCVI. Sixteen carotid BCVI underwent endovascular intervention (EI) and 19 suffered a stroke. In carotid BCVI stroke rates increased sequentially with BCVI grade except in grade 3. There was a stroke rate of 12% in grade 1 carotid BCVI, 18% in grade 2, 6% in grade 3, and 31% in grade 4. In subgroup analysis for grade 2 carotid BCVI, BCVI with > 50% and ≤ 99% LS had higher rates of stroke (22% vs. 15%, p?=?0.44) than BCVI with ≥ 25% and ≤ 50% LS. In subgroup analysis of grade 3 carotid BCVI, BCVI with PSA and LS had higher rates of stroke (9% vs. 4%, p?=?0.48) than BCVI with PSA without LS. Higher rates of EI in grade 2 carotid BCVI with > 50% and ≤ 99% LS (22% vs. 5%, p?=?0.14) and grade 3 carotid BCVI with PSA and LS (35% vs. 4%, p?=?0.01) were noted in subgroup analysis.Conclusion
Higher percentage LS beyond the currently used BCVI grading scale has a non-significantly increased rate of stroke in both aneurysmal and non-aneurysmal BCVI. Grade 3 BCVI with PSA and LS seems to be a high-risk subgroup. Use of EI confounds modern measurement of stroke risk in higher LS BCVI. 相似文献8.
Angela J. Jacques-Tiura Deborah A. Ellis April Idalski Carcone Sylvie Naar Kathryn Brogan Hartlieb Elizabeth K. Towner Thomas N. Templin K.-L. Catherine Jen 《The Journal of adolescent health》2019,64(3):355-361
Objective
Successful weight loss interventions for African-Americans adolescents are lacking. Cognitive-behavioral interventions seek to develop weight loss skills (e.g., counting calories, goal setting, managing one's environment). Little is known about how well adolescents implement such skills in their daily lives. Study aims were to (1) examine weight loss skills utilization at midpoint and end of a 6-month cognitive-behavioral/motivational interviewing weight loss sequential multiple assignment randomized trial (SMART), and (2) determine if greater skill utilization predicted weight loss at treatment end and 3 months post-treatment.Method
One hundred and eighty six African-Americans adolescents with obesity and their caregiver were first randomly assigned to complete 3 months of cognitive-behavioral and motivational interviewing family-based weight loss treatment in their home or in the research office (Phase 1). Nonresponders (i.e., those who lost < 3% of initial weight, n?=?161) were rerandomized to 3 months of continued skills training (n?=?83) or contingency management (n?=?78) for Phase 2; responders were allocated to 3 months of relapse prevention (n?=?20). Adolescents’ frequency of weight loss skills utilization was assessed via questionnaire at treatment midpoint and end.Results
Higher treatment attendance was associated with better skill utilization. Higher skill utilization was associated with more weight loss at treatment end, whereas higher baseline confidence was associated with more weight loss at follow-up.Conclusions
This study indicates the importance of attending weight loss intervention sessions to develop and strengthen weight loss skills in African-American adolescents with obesity, and strengthening confidence to use such skills for continued weight loss. 相似文献9.
10.